SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential ...

Resubmission of NDA for ZYNQUISTA - in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo Nordisk Capital raise, development ...

Google might be interested in smart glasses for the first time since Google Glass, but it’s not particularly interested in saying so—at least not in those exact terms. During the company’s two-hour ...

Is the millennial nostalgia economy losing its power? One recent trend suggests that might be the case.

The director opens up about his film on the former Beatles' final interview, why that conversation still resonates, and using ...

Forget claiming to be the unofficial fifth member of the Beatles, former A Current Affair host Tracy Grimshaw is now the ...

It costs $50K less than Range Rover over 5 years with 10-year warranty, luxury features, and 375hp V6 engine.

In today’s world of hyper-connectivity and digital convenience, a car’s infotainment system is no longer just a nice bonus but a central pillar of the driving experience. From seamless smartphone ...

Three weeks after taking over as CEO of Lexicon Pharmaceuticals back in 2024, Michael Exton suggested the company close its commercial operations. He knew the Texas-based biopharma needed to change ...

It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...

THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update ...